Myelodysplastic syndrome after COVID-19 infection in a living-donor kidney transplant recipient: a case report and literature review
- 1Department of Internal Medicine, Fujita Memorial Hospital
Abstract
Background Myelodysplastic syndrome (MDS) after kidney transplantation is rare, and its association with coronavirus disease 2019 (COVID-19) is unclear. Case report A 57-year-old man was treated with maintenance hemodialysis for end-stage kidney disease presumed to have been caused by chronic glomerulonephritis diagnosed 10 years earlier. After 1 year, he received an ABO-compatible living-donor kidney transplant from his sister. Renal graft function remained stable thereafter, with serum creatinine levels ranging from 1.49 to 1.62 mg/dL. Two years before presentation, he was hospitalized for COVID-19 that did not respond to oral molnupiravir but resolved after intravenous remdesivir therapy. However, following the COVID 19 infection, nucleated red blood cells and immature myeloid cells were persistently observed in his peripheral blood. Laboratory analyses showed hemoglobin 16.3 g/dL, white blood cell count 5700/μL, neutrophil count 2896/μL and platelet count 117,000/μL. Bone marrow aspiration revealed 1.4% myeloblasts, dysplastic erythroid cells with nuclear atypia, and megakaryocytes with poor platelet production and release, leading to a diagnosis of MDS. Cytogenetic analysis revealed trisomy 8, and Wilms’ tumor 1 messenger RNA (WT1 mRNA) expression was elevated to 690 copies/μgRNA, suggesting a risk of leukemic transformation. Although hematopoietic stem cell transplantation was considered because of his age, no suitable related donor was available, as the kidney donor sister had developed rheumatoid arthritis. Registration with the bone marrow donor program is currently under consideration. Conclusions We experienced a case of MDS diagnosed after COVID-19 in a kidney transplant recipient. Persistent appearance of immature blood cells after COVID-19 infection may warrant careful hematological evaluation in immunocompromised patients, including kidney transplant recipients.
Related
- A fatal case of cerebral scedosporiosis caused by Scedosporium boydii in a kidney transplant recipient: A case report and literature review
- Pulmonary mucormycosis due to Rhizopus homothallicus in a kidney transplant recipient complicated by massive hemoptysis: A case report with review of literature.
- Disseminated Mucor indicus Infection in a Heart Transplant Recipient: Complementary Conventional and Sequencing-Based Diagnostic Approaches
- Wearable echocardiography enables real-time perioperative monitoring in a pediatric liver transplant recipient with hepatopulmonary syndrome and pulmonary arteriovenous malformations: a case report.
- Crowned Dens Syndrome Mimicking Septic Arthritis in a Renal Transplant Recipient.
BibTeX
@article{miyazaki2026myelodysplastic,
title = {{Myelodysplastic syndrome after COVID-19 infection in a living-donor kidney transplant recipient: a case report and literature review}},
author = {Ryoichi Miyazaki and Kyoko Miyagi and Kazuhiko Igarashi},
journal = {Renal Replacement Therapy},
year = {2026},
month = oct,
doi = {10.1186/s41100-026-00783-3},
url = {https://doi.org/10.1186/s41100-026-00783-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Myelodysplastic syndrome after COVID-19 infection in a living-donor kidney transplant recipient: a case report and literature review
AU - Ryoichi Miyazaki
AU - Kyoko Miyagi
AU - Kazuhiko Igarashi
PY - 2026
DA - 2026/10/25
JO - Renal Replacement Therapy
DO - 10.1186/s41100-026-00783-3
UR - https://doi.org/10.1186/s41100-026-00783-3
AB - Background Myelodysplastic syndrome (MDS) after kidney transplantation is rare, and its association with coronavirus disease 2019 (COVID-19) is unclear. Case report A 57-year-old man was treated with maintenance hemodialysis for end-stage kidney disease presumed to have been caused by chronic glomerulonephritis diagnosed 10 years earlier. After 1 year, he received an ABO-compatible living-donor kidney transplant from his sister. Renal graft function remained stable thereafter, with serum creatinine levels ranging from 1.49 to 1.62 mg/dL. Two years before presentation, he was hospitalized for COVID-19 that did not respond to oral molnupiravir but resolved after intravenous remdesivir therapy. However, following the COVID 19 infection, nucleated red blood cells and immature myeloid cells were persistently observed in his peripheral blood. Laboratory analyses showed hemoglobin 16.3 g/dL, white blood cell count 5700/μL, neutrophil count 2896/μL and platelet count 117,000/μL. Bone marrow aspiration revealed 1.4% myeloblasts, dysplastic erythroid cells with nuclear atypia, and megakaryocytes with poor platelet production and release, leading to a diagnosis of MDS. Cytogenetic analysis revealed trisomy 8, and Wilms’ tumor 1 messenger RNA (WT1 mRNA) expression was elevated to 690 copies/μgRNA, suggesting a risk of leukemic transformation. Although hematopoietic stem cell transplantation was considered because of his age, no suitable related donor was available, as the kidney donor sister had developed rheumatoid arthritis. Registration with the bone marrow donor program is currently under consideration. Conclusions We experienced a case of MDS diagnosed after COVID-19 in a kidney transplant recipient. Persistent appearance of immature blood cells after COVID-19 infection may warrant careful hematological evaluation in immunocompromised patients, including kidney transplant recipients.
SN - 2059-1381
ER -